Epidural Nalbuphine Versus Dexmedetomidine as Adjuvants to Bupivacaine in Lower Limb Surgeries

Sponsor
Zagazig University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05041270
Collaborator
(none)
23
1
3
5
4.6

Study Details

Study Description

Brief Summary

Combined spinal epidural anesthesia (CSE) with bupivacaine alone is not sufficient to cover pain sequel during lower limb surgeries.

Previous studies used addition of either Nalbuphine or dexmedetomidine to bupivacaine in epidural anesthesia giving a good result in pain control.

In this study the investigators will evaluate and compare the addition of either Nalbuphine or dexmedetomidine to bupivacaine in epidural anesthesia to evaluate the analgesic efficacy of either drug.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Surgical patients need adequate and effective intraoperative anesthesia and postoperative analgesia. Neuroaxial block including lower limb spinal and epidural blocks have a long history of effective anesthesia and lower limb pain relief. Spinal anesthesia is a simple method requiring small dose of local anesthetic agent to give immediate and effective sensory and motor block. But one of its major side effects is hypotension and difficulty in controlling the level of the block [1]. Meanwhile, epidural anesthesia is a safe, well-practiced, not expensive neuroaxial block technique that provides intraoperative anesthesia and postoperative analgesia. So, the combined spinal epidural block (CSE) aims to achieve intense sensory and motor anesthesia and prolong the duration of analgesia intraoperative extending to postoperative period [2].

Neuroaxial anesthesia and analgesia provide perfect analgesic effect by inhibiting nociceptive transmission from peripheral to central neuronal system, but this advantage limited by short half-life of the current local anesthetics. Bupivacaine is a local anesthetic which belongs to amide group of anesthetic agents that has been widely used for local infiltration, peripheral nerve block, spinal and epidural anesthesia and despite relatively long duration of action, still has insufficient time for postoperative analgesia [3].

Several neuroaxial adjuvants such as (opioids, dexamethasone, magnesium sulphate, midazolam and dexmedetomidine) can be added to local anesthetics to prolong its duration of anesthesia and decrease the dose requirement of local anesthetics [4].

Nalbuphine, a derivative of 14-hydroxy morphine is a strong analgesic with mixed kappa agonist and µ antagonist properties. Its potency is equal to morphine, but exhibits a ceiling effect on respiratory depression. It has the potential to maintain and enhance µ-opioid based anesthesia while simultaneously mitigating the µ-opioid side effects [5].

Dexmedetomidine is an imidazole compound. It is a highly selective α-2 adrenergic agonist with an affinity 8 times more specific when compared to clonidine. It has sedative, sympatholytic and analgesic effects that blunt cardiovascular responses both intraoperative and in the perioperative period. Patients remain calm and sedated when undisturbed but arouse readily with stimulation [6]. Dexmedetomidine causes manageable hypotension and bradycardia, but the striking feature of this drug is the lack of opioid-related adverse effects like respiratory depression, pruritis, nausea, and vomiting [7].

Study Design

Study Type:
Interventional
Anticipated Enrollment :
23 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The patients will be divided randomly by a computer-generated randomization table into three equal groupsThe patients will be divided randomly by a computer-generated randomization table into three equal groups
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description:
triple blinded (patient, anesthesiologist in the operating room and outcomes assessor)
Primary Purpose:
Treatment
Official Title:
Epidural Nalbuphine Versus Dexmedetomidine as Adjuvants to Bupivacaine in Lower Limb Surgeries Under Combined Spinal-epidural Anesthesia
Actual Study Start Date :
Aug 16, 2021
Anticipated Primary Completion Date :
Dec 15, 2021
Anticipated Study Completion Date :
Jan 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: control group

patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline).

Drug: normal saline
Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min. top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline).

Active Comparator: dexmedetomidine group

patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume)

Drug: Dexmedetomidine
Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min. top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume).

Active Comparator: nalbuphine group

patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume)

Drug: Nalbuphine
Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min. top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume).

Outcome Measures

Primary Outcome Measures

  1. Duration of epidural analgesia [within 24 hour postoperative]

    time elapsed from epidural injection of LA until VAS score (≥3)

  2. Maximum level of sensory blockade [after 30 min of administering the local anesthetic in the epidural space]

    the maximum sensory dermatome level after 30 min of administering the local anesthetic in the epidural space

Secondary Outcome Measures

  1. number of top up doses required [within 24 hour postoperative]

    When sensory block regress to T12 dermatome Epidural bolus dose will be given

  2. assessment of changes in patient's level of sedation [Sedation scores will be recorded just before the initiation and 2 hours postoperatively]

    assessment of patient's level of sedation using Ramsey sedation score; where 1=patient is anxious and agitated or restless, or both. 2= Patient is co-operative, oriented, and tranquil. 3= Patient responds to commands only. 4= Patient exhibits brisk response to light glabellar tap or loud auditory stimulus. 5= Patient exhibits a sluggish response to light glabellar tap or loud auditory stimulus. 6= Patient exhibits no response.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patient acceptance.

  • BMI 25-29.9 kg/m2.

  • ASA I and ASA II.

  • Scheduled for elective lower limb orthopedic surgeries under (CSE) block.

Exclusion Criteria:
  • Patient with known allergy to study drugs,

  • Patients suffering from severe chronic diseases (cardiac, renal, hepatic and neurological or diabetes),

  • Patients with infection at the site of spinal-epidural block,

  • Drug addict patients,

  • Patients on long term steroid therapy,

  • Patients with abnormalities in vertebral spine,

  • Mentally retarded or uncooperative patients,

  • Patients receive anti-coagulant therapy or suspected coagulopathy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 faculty of medicine, Zagazig university Zagazig Elsharqya Egypt 44519

Sponsors and Collaborators

  • Zagazig University

Investigators

  • Study Director: Howaida A Kamal, MD, Faculty of medicine, zagazig university, Zagazig, Elsharqya, Egypt, 44519

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Rehab Abd-Allah Wahdan, lecturer of anesthesia and surgical intensive care, Zagazig University
ClinicalTrials.gov Identifier:
NCT05041270
Other Study ID Numbers:
  • 16-8-2021
First Posted:
Sep 13, 2021
Last Update Posted:
Sep 20, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Rehab Abd-Allah Wahdan, lecturer of anesthesia and surgical intensive care, Zagazig University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 20, 2021